China Sky One Medical, Inc. Obtains SFDA Approval for Diclofenac Sodium...( HARBIN China June 2 Asia-FirstCal...),Health

HARBIN, China, June 2 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it obtained approval from the State Food and Drug Administration (SFDA) in China for the production of Diclofenac Sodium eye drops. The document number for the drug is 2009S02063.

Diclofenac Sodium eye drops are used to treat uveitis, keratitis and sclerotitis, conditions that affect the eye. They are able to inhibit new formations of unwanted vessels in the cornea and to reduce inflammation after various types of eye operations, such as laser treatment, cataract surgery and intraocular lens operations. Diclofenac Sodium eye drops also help cure seasonal conjunctivitis and allergic conjunctivitis. The generic drops are prescription medicines that are included in medical insurance catalogues in China and they will be available to consumers from China Sky One Medical in August 2009. Management expects that there will be a strong market for Diclofenac Sodium eye drops and that they will contribute $0.5 million to revenues in the first year of sales.

"China Sky One Medical has received production approvals for seven new drugs in 2009 and we greatly appreciate the strong efforts by our R&D and sales teams in bringing new drugs to market," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "With the intelligence from our sales team, our R&D professionals can identify drugs that have strong market potential. We feel confidence that our robust product portfolio will create long term value for our shareholders."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corp
'/>"/>